Expanding anti-CD38 immunotherapy for lymphoid malignancies

Area of Science:

• Immunotherapy
• Hematologic Oncology
• Molecular Biology

Background:

• Lymphoid neoplasms, including multiple myeloma (MM), are significant causes of cancer mortality.
• CD38 is a surface glycoprotein highly expressed on malignant plasma cells and other lymphoid cells, making it a promising immunotherapy target.
• Existing CD38-targeting antibodies like daratumumab are approved for MM and investigated in other blood cancers.

Purpose of the Study:

• To develop and evaluate chimeric antigen receptor (CAR) T cells targeting CD38 for lymphoid malignancies.
• To investigate the synergistic effects of all-trans retinoic acid (ATRA) with CD38-CAR T cells and daratumumab.

Main Methods:

• Generation of CD38-targeting CAR T cells.
• In vitro cytotoxicity assays against various CD38-expressing lymphoid cancer cell lines.
• In vivo efficacy studies using mouse xenograft models.
• Evaluation of combination therapy with ATRA, CD38-CAR T cells, and daratumumab.

Main Results:

• CD38-CAR T cells demonstrated significant inhibition of multiple CD38-high lymphoid cancers, including MM, mantle cell lymphoma, and T-cell acute lymphoblastic leukemia, in vitro and in vivo.
• All-trans retinoic acid (ATRA) increased CD38 expression on CD38-low cancer cells.
• ATRA enhanced the anti-tumor activity of both daratumumab and CD38-CAR T cells in xenograft models.

Conclusions:

• CD38-CAR T cells offer a potential new immunotherapy for a wide range of lymphoid malignancies.
• Incorporating ATRA with daratumumab or CD38-CAR T cells may improve treatment outcomes for lymphoid cancers.
• These findings support the expansion of anti-CD38 immunotherapy strategies.